International experiences of promoting generics use and its implications to China

Journal of Evidence-Based Medicine

Volumn 6, Issue 2, 2013, Pages 74-80

  Sun, Jing ^a  

^a Pharmaceutical Policy Research Theme Group   (China)

Author keywords

Generics; Generics substitution; Market competition; Price; Reimbursement

Indexed keywords

GENERIC DRUG;

ARTICLE; CHINA; CHINESE MEDICINE; COMPETITION; COST CONTROL; DRUG COST; DRUG INDUSTRY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; INCOME; INSTITUTIONALIZATION; INSURANCE; JOINT VENTURE; PATENT; PRESCRIPTION; PRIORITY JOURNAL; PROBLEM IDENTIFICATION; PROBLEM SOLVING; PROSPECTIVE PAYMENT; PUBLIC HEALTH; QUALITY CONTROL; REIMBURSEMENT; SYSTEMATIC REVIEW (TOPIC);

GENERICS; GENERICS SUBSTITUTION; MARKET COMPETITION; PRICE; REIMBURSEMENT;

CHINA; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INTERNATIONALITY;

EID: 84884385588     PISSN: 17565383     EISSN: 17565391     Source Type: Journal    
DOI: 10.1111/jebm.12030     Document Type: Article

References (18)

1. Holmes CB, Coggin W, Jamieson D, Mihm H, Granich R, Savio P, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. Journal of the American Medical Association 2010; 304: 313-20.
2. Cameron A, Laing R. Cost savings of switching private sector consumption from originator brand medicines to generic equivalents. Background Paper 35, Geneva: World Health Organization, 2010. http://www.who.int/healthsystems/topics/financing/healthreport/35MedicineCostSavings.pdf. Accessed on 10 January 2013.
3. China Southern Pharmaceuticals and Economics Research Institute. China Pharmaceutical Industry Competition Capacity Analysis-Visions of the Chinese Pharmaceutical Industry Competition Capacity with the Global View. Guangzhou: China Southern Pharmaceuticals and Economics Research Institute, 2009.
4. IMS. The 2009 Revision of the National Reimbursement Drug List (NRDL). Beijing: IMS Intelligence Applied, 2009.
5. Liu J. Health insurance fund is suspected to be depleted by high price medicines of foreign firms. Southern Metropolis. http://www.menet.com.cn/Articles/Marketing/201208/201208200928232823_76158.html (accessed 20 August 2012.)
6. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. Generics and Biosimilars Initiative Journal 2012; 1(2): 44-51.
7. Gouya G, Reichardt B, Bidner A, Weissenfels R, Wolzt M. Partial reimbursement of prescription charges for generic drugs reduces costs of both health insurances and patients. Wiener Klin Wochenschr 2008; 120(3-4): 89-95.
8. Rothberg AD, Blignault J, Serfontein CB, Valodia B, Eekhout S, Pels LM. Experience of a medicines reference-pricing model. South African Medical Journal 2004; 94(3): 183-8.
9. Kaplana WA Ritzb LS, Vitelloc M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012; 106(3): 211-24.
10. Sun J. Comparison of public procurement prices of essential medicines between China and developing countries in the Western Pacific Region and its implications. China Pharmacy 2010; (44): 4137-9.
11. Ford N, Wilson D, Chaves GC, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 2007; 21(Suppl 4): S21-9.
12. Kessomboon N, Limpananont J, Kulsomboon V, Maleewong U, Eksaengsri A, Paothong P. Impact on access to medicines from TRIPS-plus: a case study of Thai-US FTA. Southeast Asian Journal of Tropical Medicine and Public Health 2010; 41(3): 667-77.
13. Akaleephana C, Wibulpolprasertb S, Sakulbumrungsilc R, Luangruangrongd P, Jitraknatheee A, Aeksaengsrif A, et al. Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPS-plus proposal. Health Policy 2009; 91(2): 174-82.
14. Supakankunti S, Janjaroen WS, Tangphao O, Ratanawijitrasin S, Kraipornsak P, Pradithavanij P. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand. Bulletin of the World Health Organization 2001; 79(5): 461-70.
15. National Center for AIDS/STD Control and Prevention. China 12th Five Year Plan Strategy for Safe Supply of Antivirals. Unpublished report. Beijing: China Center for Disease Control and Prevention, 2011.
16. The South Center. Strategies to Promote Access to Medicines and Intellectual Property Right Protection Project Report. Unpublished report. Geneva: The South Center, 2012.
17. Meyer JC, Summers RS, Möller H. Randomized, controlled trial of prescribing training in a South African province. Medical Education 2001; 35(9): 833-40.
18. Health Development Research Center of MoH, China. China National Health Account Report. Beijing: Ministry of Health of China, 2011.